Ms. Gisela S
Pharamaceutical Sciences
Nordic Nanovector
Norway
Biography
Dr Schwab is president product development and medical affairs and chief medical officer Exelixis Inc, where she has held several leading positions since 2006. She has also held the position of senior vice president and chief medical officer at Abgenix Inc, a human antibody-based drug development company. Her background includes different positions of Amgen Inc, most recently as director of clinical research and haematology/oncology therapeutic area team leader. Dr Schwab has served as a director of the board of Topotarget A/S, a publicly-held biopharmaceutical company. She currently serves as director of the board of Cellerant Therapeutics Inc., a privately held biopharmaceutical company. She received her doctor of medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda, MD, USA, and is board-certified in internal medicine and haematology and oncology. Dr Schwab has served as a director in the company since March 2015. She is an independent director of the board. Dr Schwab is president product development and medical affairs and chief medical officer Exelixis Inc, where she has held several leading positions since 2006. She has also held the position of senior vice president and chief medical officer at Abgenix Inc, a human antibody-based drug development company. Her background includes different positions of Amgen Inc, most recently as director of clinical research and haematology/oncology therapeutic area team leader. Dr Schwab has served as a director of the board of Topotarget A/S, a publicly-held biopharmaceutical company. She currently serves as director of the board of Cellerant Therapeutics Inc., a privately held biopharmaceutical company. She received her doctor of medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda, MD, USA, and is board-certified in internal medicine and haematology and oncology. Dr Schwab has served as a director in the company since March 2015. She is an independent director of the board.
Research Interest
Business Management
